San­doz, Pol­phar­ma score Eu­ro­pean ap­proval for first Tysabri biosim­i­lar for mul­ti­ple scle­ro­sis

Fol­low­ing quick­ly on the heels of US biosim­i­lar ap­provals, Am­s­ter­dam-based Pol­phar­ma Bi­o­log­ics scored a Eu­ro­pean Com­mis­sion au­tho­riza­tion for its Tysabri (na­tal­izum­ab) biosim­i­lar for mul­ti­ple scle­ro­sis, the com­pa­ny an­nounced Tues­day.

The biosim­i­lar, mar­ket­ed as Tyruko, was de­vel­oped by Pol­phar­ma but will be com­mer­cial­ized by its part­ner San­doz, thanks to a 2019 agree­ment. The FDA ap­proved Tyruko in Au­gust, mak­ing it the first-ever na­tal­izum­ab biosim­i­lar in the US. The EC au­tho­riza­tion al­so marks the first biosim­i­lar for the drug to come to mar­ket in Eu­rope.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER